Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

First time blood donors face high risk of adverse events

26 Jul 2017
The shortage of blood donations has led to a black blood market in India

Young age, high haemoglobin and lower weight increase the risk of adverse events in whole blood donors, a new study has shown. Moreover, first time donors also suffer from higher risks of adverse events.

An analysis of a cohort of 18,936 adult, healthy whole blood donors showed that the overall incidence rate of adverse events was 1.1 percent (n=208). Mild adverse events comprised 0.65 percent (n=123) while severe events comprised 0.45 percent (n=85).

Incidence rate of adverse events was significantly higher in donors <30 years of age (1.5 percent; p<0.001), with haemoglobin levels >15 g/dL (1.3 percent; p=0.005) and with weight <75 kg (1.6 percent; p<0.001).

Compared with previous donors, first time donors had significantly higher incidence rate of adverse events (0.6 vs 1.6 percent; p<0.001).

Multivariate analysis revealed that age <30 years (adjusted relative risk [ARR], 1.58; 95 percent CI, 1.18 to 2.12; p=0.002), high haemoglobin levels (ARR, 1.30; 1.15 to 1.46; p<0.001) and body weight <75 kg (ARR, 1.71; 1.29 to 2.27; p<0.001) were all significant predictors of adverse events following whole blood donation.

First-time donors (ARR, 2.21; 1.64 to 2.97; p<0.001) were also at elevated risks of adverse events after adjusting for potential confounders.

Dizziness was the leading mild adverse event with an incidence rate of 84.6 percent. This was followed by pallor (75.5 percent). On the other hand, hypertension (14.4 percent) and syncope (13.0 percent) were the most frequent severe adverse events reported.

There were no significant differences in the incidence rates of mild and severe adverse events between the different significant risk predictors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.